Hubei Hongyuan Pharmaceutical Technology (301246) Stock Overview
Produces and sells pharmaceutical products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
301246 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.92 |
| 52 Week High | CN¥23.15 |
| 52 Week Low | CN¥11.63 |
| Beta | 1.08 |
| 1 Month Change | -18.73% |
| 3 Month Change | 12.65% |
| 1 Year Change | 10.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301246 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.9% | -1.2% | 0.3% |
| 1Y | 10.6% | 12.0% | 16.8% |
Return vs Industry: 301246 underperformed the CN Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: 301246 underperformed the CN Market which returned 16.8% over the past year.
Price Volatility
| 301246 volatility | |
|---|---|
| 301246 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 301246's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301246's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,169 | Shuangxi Xu | www.hbhypharm.com |
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. It also is involved in the production and sales of triamines, guanine and other products; research and development, production, and sales of pharmaceutical preparations; trading of APIS, pharmaceutical intermediates, organic chemical raw materials, etc.; fluoride salts and other fluorine-containing chemical products; and pharmaceutical wholesale, retail, etc. Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Fundamentals Summary
| 301246 fundamental statistics | |
|---|---|
| Market cap | CN¥6.71b |
| Earnings (TTM) | CN¥14.22m |
| Revenue (TTM) | CN¥1.77b |
Is 301246 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301246 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.77b |
| Cost of Revenue | CN¥1.58b |
| Gross Profit | CN¥182.58m |
| Other Expenses | CN¥168.36m |
| Earnings | CN¥14.22m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.036 |
| Gross Margin | 10.34% |
| Net Profit Margin | 0.81% |
| Debt/Equity Ratio | 14.8% |
How did 301246 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/14 15:02 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.